Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO) (HY286296)

Name: Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO)
Brand: abinScience
SKU: HY286296
Price: 370 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HY286296
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	BSI-001
Biological activity	BSI-001 binds strongly to BT-474 and SK-BR-3 cells with overexpressed HER2 [1]. BSI-001 (100 nM, serially diluted; 3-6 days) exerts weak inhibitory effects on the proliferation of HER2-positive cancer cells when used alone, but it exerts potent synergistic anti-proliferative effects in multiple HER2-positive cancer cell lines when combined with Trastuzumab () at a fixed dose ratio of 1:1 [1]. BSI-001 (72 h) potently inhibits the migration of BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 72 h) = induces late-stage apoptosis and PARP cleavage in BT-474 cells when combined with Trastuzumab [1]. BSI-001 (100 nM; 3 days) reduces the total HER2 protein level in BT-474 cells and inhibits HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab [1]. . In combination with Trastuzumab, showed substantially enhanced BT-474 cell proliferation inhibition compared to single agents. Showed stronger synergism between 5G9 and trastuzumab. In SK-BR-3, AU-565, and NCI-N87 cells, the combination of 5G9 and trastuzumab reduced cell viability more effectively. Apoptosis Analysis [1] Cell Line: HER2-positive human breast cancer BT-474 cells Concentration: 100 nM Incubation Time: 72 h Result: Resulted in a significantly lower number of viable BT-474 cells and a higher level of late-stage apoptosis combinated with Trastuzumab, compared to the trastuzumab-pertuzumab combination.
Expression system	Mammalian cells
Clonality	Monoclonal
Target	p185erbB2, HER2, NGL, Tyrosine kinase-type cell surface receptor HER2, NEU, MLN 19, Proto-oncogene Neu, MLN19, ERBB2, Proto-oncogene c-ErbB-2, CD340, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P04626
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	BSI-001, BSI001, BSI001
Background	Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu).
References	1. Ding X, et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine. 2020 Oct;60:102996. [HY286296]
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for Research Grade Anti-Human CD340/ERBB2/HER2/NEU (BSI-001)

References

Datasheet

Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human ErbB2/Her2 Reference Antibody (BSI-001, RUO) (HY286296)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us